Artificial organs

Cochlear Implant System Market Revenue to Cross USD 2.2B by 2027: Global Market Insights, Inc.

Retrieved on: 
Thursday, February 25, 2021
Life sciences, Medical technology, Branches of biology, Neuroprosthetics, Otology, Artificial organs, Audiology, Bionics, Sonova, Cochlear implant, Implant, Cochlear

SELBYVILLE, Del., Feb. 25, 2021 /PRNewswire/ --According to the latest report "Cochlear Implant System Market by Product (Unilateral Implant, Bilateral Implant), End-user (Adult, Pediatric), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights, Inc., the market valuation of cochlear implant systems will cross $2.2 billion by 2027.

Key Points: 
  • SELBYVILLE, Del., Feb. 25, 2021 /PRNewswire/ --According to the latest report "Cochlear Implant System Market by Product (Unilateral Implant, Bilateral Implant), End-user (Adult, Pediatric), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights, Inc., the market valuation of cochlear implant systems will cross $2.2 billion by 2027.
  • For instance, in December 2020, Advanced Bionics that collaborated with Phonak received the U.S. FDA approval for their cochlear implant product.
  • The increasing prevalence of hearing loss and impairment will contribute to the cochlear implant system market demand.
  • The pediatric segment in the cochlear implant system market accounted for USD 580 million in 2020.

Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation

Retrieved on: 
Tuesday, January 19, 2021
Biotechnology, General Health, Medical devices, Health, Clinical trials, Audiology, Otology, Otorhinolaryngology, Branches of biology, Health sciences, Artificial organs, Bionics, Neuroprosthetics, Cochlear implant, Cochlear, Hearing loss, Implant

But preserving acoustic hearing in patients with less severe forms of hearing loss who receive cochlear implants could provide a substantial benefit to this population, said Nawal Ouzren, CEO of Sensorion.

Key Points: 
  • But preserving acoustic hearing in patients with less severe forms of hearing loss who receive cochlear implants could provide a substantial benefit to this population, said Nawal Ouzren, CEO of Sensorion.
  • The preclinical program was conducted as part of a collaboration between Sensorion and Cochlear (ASX: COH), the global leader in implantable hearing solutions.
  • The study was designed to determine whether SENS-401 has the potential to improve preservation of residual acoustic hearing after cochlear implantation.
  • Either SENS-401 or a placebo was delivered via an eluting electrode in an established pre-clinical model of cochlear implantation.

Global Cochlear Implant (Unilateral & Bilateral) Market Size, Share, Trends Analysis & Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 10, 2020
Biotechnology, Health, Other Health, Medical devices, Otology, Medical technology, Branches of biology, Biotechnology, Artificial organs, Medical devices, Neuroprosthetics, Audiology, Cochlear implant, Implant, Cochlear, Hearing aid

The "Cochlear Implant Market Size, Share & Trends Analysis Report by Type Of Fitting (Unilateral Implant, Bilateral Implant), by End Use (Adult, Pediatric), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cochlear Implant Market Size, Share & Trends Analysis Report by Type Of Fitting (Unilateral Implant, Bilateral Implant), by End Use (Adult, Pediatric), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global cochlear implant market size is expected to reach USD 3.3 billion by 2027, expanding at a CAGR of 10.6% from 2020 to 2027.
  • Competition from technologically advanced, lightweight, and other effective hearing aids, bionic ear, and middle ear implants may pose a threat to cochlear implants.
  • The Center of Devices and Radiological Health (CDRH) is responsible for the regulation of cochlear implant devices.

Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Monday, November 16, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Ophthalmology, Branches of biology, Organ systems, Emerging technologies, Macular degeneration, Senescence, Geographic atrophy, Retina, Artificial organs, Eye, Gene therapy of the human retina, Photovoltaic retinal prosthesis, OpRegen, Dry AMD, Lineage Cell Therapeutics, Inc.

OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).

Key Points: 
  • OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
  • The final four patients in the study were treated during November and will provide additional visual acuity data in the coming months.
  • These new data increasingly suggest to us that treatment with OpRegen can provide clinically meaningful outcomes in dry AMD patients with GA, particularly for those with earlier-stage disease, stated Brian M. Culley, Lineage CEO.
  • The results were presented at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020).

Global Retinal Implants Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 4, 2020
Medical devices, Health, Medical technology, Prosthetics, Medicine, Biomedical engineering, Biotechnology, Medical devices, Emerging technologies, Artificial organs, Retinal implant, Implant, Visual prosthesis

North America is expected to generate the highest revenue in the global retinal implant market over the forecast period.

Key Points: 
  • North America is expected to generate the highest revenue in the global retinal implant market over the forecast period.
  • High prevalence of degenerative conditions and technological advancements may drive growth of the North America retinal implants market over the forecast period.
  • Retinal implants are manufactured by few companies currently and only four types of implants have been approved by the US FDA.
  • Added to that, the favourable reimbursement facility for the retinal implant is acting as a driver for the growth of this market in this region.

MED-EL Named Hearing Technology “Innovator of the Year”

Retrieved on: 
Monday, October 19, 2020
Science, Software, Research, Audio, Video, Health, Medical devices, Technology, Other Health, Otology, Otorhinolaryngology, Audiology, Perception, Hearing, Auditory system, Artificial organs, Bionics, MED-EL, Cochlear implant, Electric acoustic stimulation, Hearing loss

MED-EL announced today that it has been named Innovator of the Year by the first-ever Hearing Health & Technology Matters (HHTM) Innovator Awards.

Key Points: 
  • MED-EL announced today that it has been named Innovator of the Year by the first-ever Hearing Health & Technology Matters (HHTM) Innovator Awards.
  • The Hearing Technology Innovator Awards is an international awards program designed to recognize and celebrate innovation within the hearing industry.
  • Hearing Health & Technology Matters (HHTM) is an organization dedicated to bridging the knowledge gaps in treating hearing loss.
  • MED-ELs global portfolio of hearing solutions includes cochlear implant systems, a combined Electric Acoustic Stimulation hearing implant system, and bone conduction devices.

Pixium Vision Hosting Key Opinion Leader Webinar on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD)

Retrieved on: 
Friday, October 16, 2020
Anatomy, Medical technology, Vision, Emerging technologies, Artificial organs, Eye, Medical devices, Prosthetics, Retinal implant, Macular degeneration, Macula of retina, Retina, Anatomy, Medical technology, Vision, Emerging technologies, Artificial organs, Eye, Medical devices, Prosthetics, Retinal implant, Macular degeneration, Macula of retina, Retina

Pixium Vision's management team will give an update on their Prima Bionic Vision System.

Key Points: 
  • Pixium Vision's management team will give an update on their Prima Bionic Vision System.
  • Dr. Sahel was a co-founder of Fovea Pharmaceuticals, StreetLab, GenSight Biologics, Pixium Vision, Sparing Vision.
  • Pixium Vision is conducting clinical feasibility studies of its Prima system, its miniaturized wireless sub-retinal implant, in patients who have lost their sight due to retinal degeneration associated with the dry form of Age- Related Macular Degeneration (AMD).
  • Pixium Vision has been qualified as an Innovative Company by Bpifrance
    This press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business.

Cochlear obtains FDA approval of Kanso 2 Sound Processor, first off-the-ear cochlear implant sound processor with direct smartphone connectivity

Retrieved on: 
Monday, July 6, 2020
Medical technology, Otology, Perception, Brain, Auditory system, Audiology, Artificial organs, Bionics, Cochlear, Implant, Cochlea, Cochlear Limited

The approval of the Cochlear Nucleus Kanso 2 Sound Processor, Nucleus 7 Sound Processor for Nucleus 22 Implant recipients and Custom Sound Pro fitting softwarereflects Cochlear's ongoing commitment to innovation in hearing technology, providing access to smartphone connectivity and helping to improve hearing performance, and enhancing the cochlear implant fitting experience for hearing health professionals.

Key Points: 
  • The approval of the Cochlear Nucleus Kanso 2 Sound Processor, Nucleus 7 Sound Processor for Nucleus 22 Implant recipients and Custom Sound Pro fitting softwarereflects Cochlear's ongoing commitment to innovation in hearing technology, providing access to smartphone connectivity and helping to improve hearing performance, and enhancing the cochlear implant fitting experience for hearing health professionals.
  • The Kanso 2 Sound Processor is the world's smallest1 off-the-ear cochlear implant sound processor, and it is the first and only off-the-ear cochlear implant sound processor to offer direct streaming from compatible Appleor Android devices.
  • The Kanso 2 Sound Processor also features the highest possible water resistance rating for any off-the-ear cochlear implant sound processor, giving users the freedom to live an active lifestyle.
  • At commercial availability, the Kanso 2 Sound Processor is compatible with Cochlear N24, CI24RE, CI500, Profile and Profile Plus Series Implants.

Envoy Medical Receives FDA Breakthrough Device Designation for its Fully Implanted Acclaim® Cochlear Implant

Retrieved on: 
Monday, June 29, 2020
Medical devices, FDA, Health, Surgery, Research, Science, Medical specialties, Medicine, Medical technology, Otology, Prosthetics, Audiology, Neuroprosthetics, Artificial organs, Implant, Cochlear implant, Osseointegration, Cochlear, the Fully Implanted Acclaim® Cochlear Implant, the Fully Implanted Esteem® Osseointegrated Active Middle Ear Implant, Envoy Medical Corporation

Envoy Medical Corporation , a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced that its fully implanted Acclaim cochlear implant was granted the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Envoy Medical Corporation , a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced that its fully implanted Acclaim cochlear implant was granted the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
  • The fully implanted Acclaim cochlear implant leverages the novel sensor technology from the Esteem osseointegrated AMEI.
  • The Acclaim cochlear implant leverages the proven and novel sensor technology from the fully implanted Esteem osseointegrated active middle ear implant.
  • Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem osseointegrated active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim cochlear implant, an investigational device.

Pixium Vision selected to participate in the Next French Healthcare program organized by Business France and BPI France, bolstering presence in the US

Retrieved on: 
Friday, June 19, 2020
Ophthalmology, Vision, Macular degeneration, RTT, Senescence, Organ systems, Emerging technologies, Eye, Artificial organs, Visual prosthesis, Photovoltaic retinal prosthesis

Pixium Vision will update investors on its plans for the bionic vision Prima System and increase awareness in the US of its exciting development and commercial plans.

Key Points: 
  • Pixium Vision will update investors on its plans for the bionic vision Prima System and increase awareness in the US of its exciting development and commercial plans.
  • Recent 18-month data have shown the Prima System is able to combine natural residual vision with prosthetic central vision in patients with dry age-related macular degeneration (AMD), paving the way for a pivotal study.
  • The US feasibility study is expected to resume as soon as the COVID-19 situation allows.
  • Pixium Vision is ready for the next steps of its ongoing transition from a research to a fully-fledged commercial organization, both in Europe and the US, said Lloyd Diamond, Chief Executive Officer of Pixium Vision.